Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 11 of 11

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	person-years	NUMBER
PRIMARY	Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	participants	NUMBER
SECONDARY	Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product	Throughout study, up to 2.5 years	Resistance testing was successfully completed on plasma from 301/312 HIV-1 seroconverters while on study product. 11 participants did not have a resistance result due to no stored plasma, insufficient copies of HIV-1 RNA for extraction, or PCR amplification failure.	participants	NUMBER
PRIMARY	Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	cases per 100 person-years	NUMBER
PRIMARY	Person-years of Follow-up of Oral TDF and Oral Placebo Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	person-years	NUMBER
PRIMARY	Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	participants	NUMBER
PRIMARY	Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	cases per 100 person-years	NUMBER
PRIMARY	Person-years of Follow-up of Oral TDF-FTC and Oral Placebo Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	person-years	NUMBER
PRIMARY	Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	participants	NUMBER
PRIMARY	Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms	For up to 30 months of follow-up	All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.	cases per 100 person-years	NUMBER
PRIMARY	Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse Events	Throughout study, up to 2.5 years	All participants randomized (intention-to-treat).	participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00705679/outcomes

API reference For AI assistants